ATS 2018*: An Update on Scientific Advances and Clinical Strategies in Interstitial Lung Disease (ILD)
The American Thoracic Society (ATS) International Conference was held in San Diego, California, May 18-23, 2018. The ATS international conference is the longest running, large-scale conference in the world offering groundbreaking research in pulmonary, critical care, and sleep medicine. In this activity, 2 experts summarize the key learnings from this year’s conference focusing on strategies in interstitial lung disease (ILD).
*This webcast is not endorsed by the conference organizer. Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis, and expert perspectives through conference coverage educational programs.
This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with ILD.
Upon completion of this activity, participants will be better able to do the following:
- Identify recent advances in the understanding of ILD pathophysiology, genetics, disease progression, and comorbidities
- Discuss recent advances in ILD treatment
Fernando J. Martinez, MD, MS (Program Chair)
Steven D. Nathan, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Fernando J. Martinez, MD, MS|
Consultant/Advisor: AstraZeneca, Biogen, Boehringer Ingelheim GmbH, GlaxoSmithKline LLC, Nitto, Novartis AG, Patara Pharma, Veracyte, Inc, Zambon Company S.P.A.
Grant/Research Support: AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, Gilead, GlaxoSmithKline LLC
Speakers’ Bureau: Eli Lilly and Company, Prime Education, LLC, UpToDate, Inc., WebMD, LLC
|Steven D. Nathan, MD|
Consultant/Advisor: Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd, Genentech, Inc.
Grant/Research Support: Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd, Genentech, Inc.Speakers’ Bureau: Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd, Genentech, Inc.
Non-faculty: Lyerka Miller, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at email@example.com. Additional information on the process of converting AMA PRA Category 1 Credits™ to ECMECs® can be found at: www.eaccme.eu.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Miller Medical Communications, LLC., and Boehringer Ingelheim Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician